

Executive Corridor
Darlington Memorial Hospital
Hollyhurst Road
Darlington
DL3 6HX
Switchboard Tel: 01325 38 0100
Foundation Trust Office: 01325 74 3625
Corporate Records Office: 01325 74 3700

Request for Information Reference: 06.23.55

FOI Direct line: 01325 743700
Email: cdda-tr.cddftfoi@nhs.net

Email only

10th July 2023

Dear

Freedom of Information Act 2000 – Request for Information

Thank you for submitting a request for information which we received on 20th June 2023 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to Breast Cancer Treatment and I am providing the following information in response to your specific questions:

FOI REQUEST:

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following two questions.

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	35
Abemaciclib + Fulvestrant	5
Alpelisib + Fulvestrant	1
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	0
Atezolizumab +Nab-paclitaxel/Paclitaxel	3
Capecitabine as a single agent	25
Eribulin as a single agent or in combination	1

Everolimus + Exemestane	3
Fulvestrant as a single agent	0
Lapatinib	0
Neratinib	0
Parp Inhibitors (Olaparib/Talazoparib)	0
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0
Palbociclib + Fulvestrant	19
Pembrolizumab	2
Platinum (e.g. carboplatin or cisplatin) as a single agent	0
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	17
Ribociclib + Fulvestrant	4
Sacituzumab Govitecan	3
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	0
Taxane and/or Anthracycline in combination	0
Trastuzumab as a single agent or in combination	35
Trastuzumab emtansine	0
Transtuzumab deruxtecan	8
Any other active systemic anti-cancer therapy	
Atezolizumab	2
Carboplatin + Paclitaxel	1
Denosumab	89
Docetaxel	2
Docetaxel + Cyclophosphamide	5
EC90	7
EC90 (Epirubicin + Cyclophosphamide – Dose Dense)	10
Epirubicin + Cyclophosphamide	10
Kadcycla (Trastuzumab Emtansine)	9
Paclitaxel	40
Palbociclib + Letrozole	36
Pembrolizumab + Carboplatin + Paclitaxel	7
Pembrolizumab + EC90	2
Phesgo	40
Phesgo + Docetaxel	6
Vinorelbine	3
Zoledronic Acid	126

2. Does your trust participate in any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part.

DMH – ATNEC - 1 patient

UHND – Zero

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via cdda-tr.cddftfoi@nhs.

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. More information is available on their website; www.ico.gov.uk.

Yours sincerely

Corporate Records and Freedom of Information Facilitator